Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer

British Journal of Cancer

Volumn 89, Issue 10, 2003, Pages 1837-1842

  Cameron, D A ^a   Massie, C ^a   Kerr, G ^a   Leonard, R C F ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Adjuvant; CMF; Early breast cancer; Neutropenia; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGE; AGED; AXILLARY LYMPH NODE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG DOSE REGIMEN; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

ADULT; AGE OF ONSET; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0348013443     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601366     Document Type: Review

References (12)

1. Batey MA, Wright JG, Azzabi A, Newell DR, Lind MJ, Calvert AH, Boddy AV (2002) Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Eur J Cancer 38: 1081-1089
2. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356: 1384-1391
3. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995a) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med 332: 901-906
4. Bonadonna G, Zambetti M, Valagussa P (1995b) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results (see comments). JAMA 273: 542-547
5. Cameron DA, Anderson A, Toy E, Evans TRJ, Le Vay JH, Kennedy ICS, grieve RJ, Perren TJ, Jones A, Mansi J, Crown J, Leonard RCF (2002) Block sequential adriamycin CMF - optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? Br J Cancer 87: 1365-1369
6. Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS, Schumacher M, Bastert G, Rudenstam C-M, Schmoor C, Lindtner J, Collins J, Thurlimann B, Holmberg AB, Crivellari D, Beyerle C, Neumann RLA, Goldhirsch A (2002) Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 86: 1705-1714
7. Early Breast Cancer Trialists Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, systemic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339, 1-14; 71-85
8. Early Breast Cancer Trialists Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942
9. Mayers C, Panzarella T, Tannock IF (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91: 2246-2257
10. Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM (2001) Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19: 3103-3110
11. Saarto T, Blomqvist C, Rissanen P, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75: 301-305
12. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Colangelo Ballow A, Frei III E, Henderson IC (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253-1259